{"protocolSection": {"identificationModule": {"nctId": "NCT00902538", "orgStudyIdInfo": {"id": "CS8635-A-E303"}, "organization": {"fullName": "Daiichi Sankyo", "class": "INDUSTRY"}, "briefTitle": "Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in Hypertension", "officialTitle": "Add-on Study of Hydrochlorothiazide in Patients With Moderate to Severe Hypertension Not Achieving Target Blood Pressure on Olmesartan/Amlodipine Alone"}, "statusModule": {"statusVerifiedDate": "2012-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2009-04"}, "primaryCompletionDateStruct": {"date": "2010-09", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-10", "type": "ACTUAL"}, "studyFirstSubmitDate": "2009-05-13", "studyFirstSubmitQcDate": "2009-05-14", "studyFirstPostDateStruct": {"date": "2009-05-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2011-09-06", "resultsFirstSubmitQcDate": "2011-10-17", "resultsFirstPostDateStruct": {"date": "2011-11-22", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2018-12-20", "lastUpdatePostDateStruct": {"date": "2019-01-11", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Daiichi Sankyo", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "Both Olmesartan (OLM)/Amlodipine (AML) combination and Hydrochlorothiazide (HCTZ) have proven to be efficacious and safe in lowering blood pressure, but may not always be sufficient. This study is to test efficacy and safety of the combination of OLM/AML and HCTZ in hypertensive patients whose blood pressure is not adequately controlled with OLM/AML alone. The following treatments will be included in the trial: OLM 40mg/AML 10mg; OLM 40mg/AML 10 mg/HCTZ 12.5 mg; OLM 40 mg/AML 10 mg/HCTZ 25 mg. The trial has four periods. The treatments that will be used are as follows:\n\nPeriod 1 - OLM 40mg/AML 10mg; Period 2 - OLM 40mg/AML 10mg or OLM 40mg/AML 10 mg/HCTZ 12.5 mg or OLM 40 mg/AML 10 mg/HCTZ 25 mg; Period 3 - OLM 40mg/AML 10 mg/HCTZ 12.5 mg; Period 4 - Period 3 responders: OLM 40mg/AML 10 mg/HCTZ 12.5 mg; Period 4 - Period 3 non-responders: OLM 40mg/AML 10 mg/HCTZ 12.5 mg or OLM 40 mg/AML 10 mg/HCTZ 25 mg"}, "conditionsModule": {"conditions": ["Essential Hypertension"], "keywords": ["Add on treatment", "essential hypertension"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 2204, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Olmesartan (OLM) 40mg-Amlodipine (AML) 10mg", "type": "EXPERIMENTAL", "description": "The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2.", "interventionNames": ["Drug: Olmesartan medoxomil 40 mg - Amlodipine 10 mg"]}, {"label": "Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg", "type": "EXPERIMENTAL", "description": "Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3.", "interventionNames": ["Drug: Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg"]}, {"label": "Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg", "type": "EXPERIMENTAL", "description": "Participants could start receiving this combination in randomized, double-blind, 8- week Period 2.", "interventionNames": ["Drug: Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg"]}, {"label": "OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Responders)", "type": "EXPERIMENTAL", "description": "Participants who meet their blood pressure goals in Period 3 and continued into the 8-week, double-blind Period 4 continued to receive this combination.", "interventionNames": ["Drug: OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg"]}, {"label": "OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Non-responders)", "type": "EXPERIMENTAL", "description": "Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4", "interventionNames": ["Drug: OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg"]}, {"label": "OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg (Non-responders)", "type": "EXPERIMENTAL", "description": "Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4", "interventionNames": ["Drug: OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg"]}], "interventions": [{"type": "DRUG", "name": "Olmesartan medoxomil 40 mg - Amlodipine 10 mg", "description": "Oral tablets containing Olmesartan medoxomil-Amlodipine 40-10 mg, given once daily", "armGroupLabels": ["Olmesartan (OLM) 40mg-Amlodipine (AML) 10mg"]}, {"type": "DRUG", "name": "Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg", "description": "Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.", "armGroupLabels": ["Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg"]}, {"type": "DRUG", "name": "Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg", "description": "Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.", "armGroupLabels": ["Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg"], "otherNames": ["Olmesartan 40mg-Amlodipine 10mg tablet + 2 Hydrochlorothiazide 12.5mg tablets"]}, {"type": "DRUG", "name": "OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg", "description": "Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.", "armGroupLabels": ["OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Responders)"]}, {"type": "DRUG", "name": "OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg", "description": "Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.", "armGroupLabels": ["OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg (Non-responders)"]}, {"type": "DRUG", "name": "OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg", "description": "Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.", "armGroupLabels": ["OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg (Non-responders)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg", "description": "Three cuff blood pressure measurements were taken at each visit.", "timeFrame": "baseline (8 weeks) to 16 weeks"}], "secondaryOutcomes": [{"measure": "Change in Seated Systolic Blood Pressure (SeSBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg", "description": "Three cuff blood pressure measurements were taken at each visit.", "timeFrame": "baseline (8 weeks) to week 16"}, {"measure": "Number of Subjects Achieving Blood Pressure (BP) Goal at Week 16.", "description": "Achieving blood pressure goal is defined as seated blood pressure \\<140/90 mm Hg; 130/80 mm Hg for participants with diabetes and/or other chronic renal and/or chronic cardiovascular disease. Three cuff blood pressure measurements were taken at each visit.", "timeFrame": "baseline (week 8) to week 16"}, {"measure": "Change in 24-hour Diastolic Blood Pressure (DBP) Assessed by 24-hour Ambulatory Blood Pressure Measurement (ABPM).", "description": "Three cuff blood pressure measurements were taken at each visit.", "timeFrame": "Baseline (8 weeks) to 16 weeks"}, {"measure": "Change in 24-hour Systolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.", "description": "Three cuff blood pressure measurements were taken at each visit.", "timeFrame": "Baseline (8 weeks) to 16 weeks"}, {"measure": "In Non-responders, the Change in Seated Diastolic Blood Pressure Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.", "description": "Change in seated diastolic blood pressure from the beginning to the end of Period 4. Three cuff blood pressure measurements were taken at each visit.", "timeFrame": "week 24 to week 32"}, {"measure": "In Non-responders, the Change in Seated Systolic Blood Pressure Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.", "description": "Change in seated systolic blood pressure from the beginning to the end of Period 4. Three cuff blood pressure measurements were taken at each visit.", "timeFrame": "week 24 to week 32"}, {"measure": "In Non-responders, the Number of Subject Meeting Their Blood Pressure Goals Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.", "description": "The number of non-responding participants who achieved their blood pressure goals at the end of Period 4. Achieving blood pressure goal is defined as seated blood pressure \\<140/90 mm Hg; 130/80 mm Hg for participants with diabetes and/or other chronic renal and/or chronic cardiovascular disease. Three cuff blood pressure measurements were taken at each visit.", "timeFrame": "week 24 to week 32"}, {"measure": "In Non-responders, the Change in 24-hour Diastolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.", "description": "In non-responders, the change in 24-hour diastolic blood pressure assessed by 24-hour ambulatory blood pressure measurement from the beginning to the end of Period 4.", "timeFrame": "Week 16 to week 32"}, {"measure": "In Non-responders, the Change in 24-hour Systolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.", "description": "In non-responders, the change in 24-hour systolic blood pressure assessed by 24-hour ambulatory blood pressure measurement from the beginning to the end of Period 4.", "timeFrame": "Week 16 to week 32"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female aged 18 years or older.\n* Mean trough seated systolic blood pressure (SeSBP) of \u2265 160/100 mmHg (SeSBP of \u2265 160 mmHg and seated diastolic blood pressure (SeDBP) \u2265 100 mmHg) at screening if not currently on antihypertensive medication (e.g. newly diagnosed subjects)\n\nOR:\n\nFor subjects on monotherapy: mean trough SeSBP of \u2265 150/95 mmHg (SeSBP of \u2265 150 mmHg and SeDBP \u2265 95 mmHg) at screening\n\nOR:\n\nFor subjects on any combination of antihypertensive medications that includes either hydrochlorothiazide or amlodipine or olmesartan for a duration of at least four weeks: mean trough SeSBP of \u2265 140/90 mmHg (SeSBP of \u2265 140 mmHg and SeDBP \u2265 90 mmHg) at screening\n\nOR:\n\nFor subjects on any other combination of antihypertensive medications that includes neither hydrochlorothiazide, amlodipine nor olmesartan: mean trough SeSBP \u2265 160 mmHg, mean trough SeDBP \u2265 100mmHg, at the end of the taper-off period\n\n* Subject freely signs the Informed Consent Form (ICF) after the nature of the study and the disclosure of his/her data has been explained.\n* Female subjects of childbearing potential must be using adequate contraception (female of childbearing potential is defined as one who has not been postmenopausal for at least one year, or has not been surgically sterilised, or has not had a hysterectomy at least three months prior to the start of this study \\[Visit 1\\]). Females taking oral contraceptives should have been on therapy for at least three months. Adequate contraceptives include hormonal intra-uterine devices, hormonal contraceptives (oral, depot, patch or injectable), and double barrier methods such as condoms or diaphragms with spermicidal gel or foam. If a female becomes pregnant during the study, she has to be withdrawn immediately.\n\nExclusion Criteria:\n\n* Female subjects of childbearing potential who are pregnant or lactating.\n* Subjects with serious disorders which may limit the ability to evaluate the efficacy or safety of the investigational products, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological or oncological, neurological, and psychiatric diseases. The same applies for immunocompromised and/or neutropenic subjects.\n* Subjects having a history of the following within the last six months: myocardial infarction (MI), unstable angina pectoris, percutaneous coronary intervention, heart failure, hypertensive encephalopathy, cerebrovascular accident (stroke), or transient ischaemic attack.\n* Subjects with clinically significant abnormal laboratory values at Screening, including subjects with one or more of the following:\n\n  * Aspartate aminotransferase (AST) \\> 3 times upper limit of normal (ULN)\n  * Alanine aminotransferase (ALT) \\> 3 times ULN\n  * Gamma-glutamyltransferase (GGT) \\> 3 times ULN\n  * Potassium above ULN (unless high value is due to haemolytic blood sample)\n* Subjects with secondary hypertension of any aetiology such as renal disease, phaeochromocytoma, or Cushing's syndrome.\n* Subjects with contraindication to olmesartan, amlodipine, hydrochlorothiazide, or any of the excipients.\n* Subjects with a mean SeSBP \\> 200 mmHg or mean SeDBP \\> 115 mmHg or bradycardia (heart rate \\< 50 beats/min at rest documented by mean radial pulse rate \\[PR\\] or electrocardiogram \\[ECG\\]) at Screening (Visit 1) or immediately before taking Period I study medication (Visit 2).", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"locations": [{"city": "Graz", "country": "Austria", "geoPoint": {"lat": 47.06667, "lon": 15.45}}, {"city": "Salzburg", "country": "Austria", "geoPoint": {"lat": 47.79941, "lon": 13.04399}}, {"city": "Wien", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"city": "Antwerpen", "country": "Belgium", "geoPoint": {"lat": 51.21989, "lon": 4.40346}}, {"city": "Lauwe", "country": "Belgium", "geoPoint": {"lat": 50.79479, "lon": 3.1869}}, {"city": "Leuven", "country": "Belgium", "geoPoint": {"lat": 50.87959, "lon": 4.70093}}, {"city": "Liege", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"city": "Massemen", "country": "Belgium", "geoPoint": {"lat": 50.98086, "lon": 3.87394}}, {"city": "Oostham", "country": "Belgium", "geoPoint": {"lat": 51.10374, "lon": 5.17877}}, {"city": "Haskovo", "country": "Bulgaria", "geoPoint": {"lat": 41.93415, "lon": 25.55557}}, {"city": "Pleven", "country": "Bulgaria", "geoPoint": {"lat": 43.41667, "lon": 24.61667}}, {"city": "Plovdiv", "country": "Bulgaria", "geoPoint": {"lat": 42.15, "lon": 24.75}}, {"city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"city": "Varna", "country": "Bulgaria", "geoPoint": {"lat": 43.21667, "lon": 27.91667}}, {"city": "Bilovec", "country": "Czechia", "geoPoint": {"lat": 49.75639, "lon": 18.01581}}, {"city": "Brno", "country": "Czechia", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"city": "Havlickuv Brod", "country": "Czechia", "geoPoint": {"lat": 49.60785, "lon": 15.58069}}, {"city": "Hodonin", "country": "Czechia", "geoPoint": {"lat": 48.84893, "lon": 17.13244}}, {"city": "Kladno", "country": "Czechia", "geoPoint": {"lat": 50.14734, "lon": 14.10285}}, {"city": "Kolin", "country": "Czechia", "geoPoint": {"lat": 50.02806, "lon": 15.1998}}, {"city": "Ostrava-Vitkovice", "country": "Czechia", "geoPoint": {"lat": 49.83465, "lon": 18.28204}}, {"city": "Ostrava", "country": "Czechia", "geoPoint": {"lat": 49.83465, "lon": 18.28204}}, {"city": "Praha", "country": "Czechia", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"city": "Copenhagen", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"city": "Frederiksberg", "country": "Denmark", "geoPoint": {"lat": 55.67938, "lon": 12.53463}}, {"city": "Naestved", "country": "Denmark", "geoPoint": {"lat": 55.22992, "lon": 11.76092}}, {"city": "Roskilde", "country": "Denmark", "geoPoint": {"lat": 55.64152, "lon": 12.08035}}, {"city": "Albi", "country": "France", "geoPoint": {"lat": 43.9298, "lon": 2.148}}, {"city": "Angers", "country": "France", "geoPoint": {"lat": 47.46667, "lon": -0.55}}, {"city": "Brest", "country": "France", "geoPoint": {"lat": 48.3903, "lon": -4.48628}}, {"city": "Cambrai", "country": "France", "geoPoint": {"lat": 50.16667, "lon": 3.23333}}, {"city": "Creteil", "country": "France", "geoPoint": {"lat": 48.78333, "lon": 2.46667}}, {"city": "Dijon", "country": "France", "geoPoint": {"lat": 47.31667, "lon": 5.01667}}, {"city": "Dinard", "country": "France", "geoPoint": {"lat": 48.63143, "lon": -2.06144}}, {"city": "Lyon", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"city": "Nancy", "country": "France", "geoPoint": {"lat": 48.68439, "lon": 6.18496}}, {"city": "Pessac", "country": "France", "geoPoint": {"lat": 44.81011, "lon": -0.64129}}, {"city": "Roubaix", "country": "France", "geoPoint": {"lat": 50.69421, "lon": 3.17456}}, {"city": "Strasbourg", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"city": "Tierce", "country": "France", "geoPoint": {"lat": 47.61587, "lon": -0.46609}}, {"city": "Vandoeuvre", "country": "France"}, {"city": "Villefranche de Rouergue", "country": "France", "geoPoint": {"lat": 44.35166, "lon": 2.03702}}, {"city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"city": "Dresden", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"city": "Einbeck", "country": "Germany", "geoPoint": {"lat": 51.82018, "lon": 9.86961}}, {"city": "Hamburg", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"city": "Magdeburg", "country": "Germany", "geoPoint": {"lat": 52.12773, "lon": 11.62916}}, {"city": "Muenchen", "country": "Germany", "geoPoint": {"lat": 51.60698, "lon": 13.31243}}, {"city": "Strasskirchen", "country": "Germany", "geoPoint": {"lat": 48.83071, "lon": 12.72105}}, {"city": "Villingen-Schwenningen", "country": "Germany", "geoPoint": {"lat": 48.06226, "lon": 8.49358}}, {"city": "Wermsdorf", "country": "Germany", "geoPoint": {"lat": 51.28333, "lon": 12.95}}, {"city": "Almere", "country": "Netherlands", "geoPoint": {"lat": 52.37535, "lon": 5.25295}}, {"city": "Beek en Donk", "country": "Netherlands", "geoPoint": {"lat": 51.54158, "lon": 5.62603}}, {"city": "Doetinchem", "country": "Netherlands", "geoPoint": {"lat": 51.965, "lon": 6.28889}}, {"city": "Groningen", "country": "Netherlands", "geoPoint": {"lat": 53.21917, "lon": 6.56667}}, {"city": "Losser", "country": "Netherlands", "geoPoint": {"lat": 52.26083, "lon": 7.00417}}, {"city": "Maastricht", "country": "Netherlands", "geoPoint": {"lat": 50.84833, "lon": 5.68889}}, {"city": "Bytom", "country": "Poland", "geoPoint": {"lat": 50.34802, "lon": 18.93282}}, {"city": "Gdansk", "country": "Poland", "geoPoint": {"lat": 54.35205, "lon": 18.64637}}, {"city": "Katowice", "country": "Poland", "geoPoint": {"lat": 50.25841, "lon": 19.02754}}, {"city": "Krakow", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"city": "Piotrkow Trybunalski", "country": "Poland", "geoPoint": {"lat": 51.40547, "lon": 19.70321}}, {"city": "Pulawy", "country": "Poland", "geoPoint": {"lat": 51.41655, "lon": 21.96939}}, {"city": "Siemianowice Slaskie", "country": "Poland", "geoPoint": {"lat": 50.32738, "lon": 19.02901}}, {"city": "Tarnow", "country": "Poland", "geoPoint": {"lat": 50.01381, "lon": 20.98698}}, {"city": "Torun", "country": "Poland", "geoPoint": {"lat": 53.01375, "lon": 18.59814}}, {"city": "Warszawa", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"city": "Wroclaw", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"city": "Brasov", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"city": "Cluj-Napoca", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"city": "Iasi", "country": "Romania", "geoPoint": {"lat": 47.16667, "lon": 27.6}}, {"city": "Oradea", "country": "Romania", "geoPoint": {"lat": 47.0458, "lon": 21.91833}}, {"city": "Pitesti", "country": "Romania", "geoPoint": {"lat": 44.85, "lon": 24.86667}}, {"city": "Targoviste", "country": "Romania", "geoPoint": {"lat": 44.92543, "lon": 25.4567}}, {"city": "Targu Mures", "country": "Romania", "geoPoint": {"lat": 46.54245, "lon": 24.55747}}, {"city": "Timisoara", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"city": "Ekaterinburg", "country": "Russian Federation", "geoPoint": {"lat": 56.8519, "lon": 60.6122}}, {"city": "Moscow", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"city": "Novosibirsk", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"city": "Orenburg", "country": "Russian Federation", "geoPoint": {"lat": 51.7727, "lon": 55.0988}}, {"city": "Ryazan", "country": "Russian Federation", "geoPoint": {"lat": 54.6269, "lon": 39.6916}}, {"city": "Saratov", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"city": "Smolensk", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"city": "St. Petersburg", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"city": "Tomsk", "country": "Russian Federation", "geoPoint": {"lat": 56.49771, "lon": 84.97437}}, {"city": "Yaroslavl", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"city": "Banska Bysterica", "country": "Slovakia"}, {"city": "Brastislava", "country": "Slovakia"}, {"city": "Dolny Kubin", "country": "Slovakia", "geoPoint": {"lat": 49.20983, "lon": 19.30341}}, {"city": "Kosice", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"city": "Presov", "country": "Slovakia", "geoPoint": {"lat": 48.99839, "lon": 21.23393}}, {"city": "Sahy", "country": "Slovakia", "geoPoint": {"lat": 48.07408, "lon": 18.94946}}, {"city": "La Gineta", "state": "Albacete", "country": "Spain", "geoPoint": {"lat": 39.11452, "lon": -1.99603}}, {"city": "La Roda", "state": "Albacete", "country": "Spain", "geoPoint": {"lat": 39.20735, "lon": -2.15723}}, {"city": "Port De Sagunt", "state": "Valencia", "country": "Spain"}, {"city": "Alicante", "country": "Spain", "geoPoint": {"lat": 38.34517, "lon": -0.48149}}, {"city": "Barcelona", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"city": "Elche", "country": "Spain", "geoPoint": {"lat": 38.26218, "lon": -0.70107}}, {"city": "Granada", "country": "Spain", "geoPoint": {"lat": 37.18817, "lon": -3.60667}}, {"city": "Madrid", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"city": "Palma de Mallorca", "country": "Spain", "geoPoint": {"lat": 39.56939, "lon": 2.65024}}, {"city": "Sevilla", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"city": "Valencia", "country": "Spain", "geoPoint": {"lat": 39.46975, "lon": -0.37739}}, {"city": "Vizcaya", "country": "Spain"}, {"city": "Dnipropetrovsk", "country": "Ukraine", "geoPoint": {"lat": 48.4593, "lon": 35.03864}}, {"city": "Donetsk", "country": "Ukraine", "geoPoint": {"lat": 48.023, "lon": 37.80224}}, {"city": "Ivano-Frankivsk", "country": "Ukraine", "geoPoint": {"lat": 48.9215, "lon": 24.70972}}, {"city": "Kharkiv", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"city": "Kiev", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"city": "Lviv", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"city": "Mykolayiv", "country": "Ukraine", "geoPoint": {"lat": 46.96591, "lon": 31.9974}}, {"city": "Odesa", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"city": "Simferopol", "country": "Ukraine", "geoPoint": {"lat": 44.95719, "lon": 34.11079}}, {"city": "Uzhorod", "country": "Ukraine", "geoPoint": {"lat": 48.61667, "lon": 22.3}}, {"city": "Vinnytsya", "country": "Ukraine", "geoPoint": {"lat": 49.23278, "lon": 28.48097}}, {"city": "Yalta", "country": "Ukraine", "geoPoint": {"lat": 44.50218, "lon": 34.16624}}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/", "infoTypes": ["STUDY_PROTOCOL", "SAP", "ICF", "CSR", "ANALYTIC_CODE"], "timeFrame": "Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.", "accessCriteria": "Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.", "url": "https://vivli.org/ourmember/daiichi-sankyo/"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The number of subjects entering Period 2 was only 808 because 1278 did not meet the entry criteria.", "recruitmentDetails": "First participant visit was 29 April 2009. The last participant follow up was 07 September 2010", "groups": [{"id": "FG000", "title": "Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg", "description": "The participants in this arm received Olmesartan(OLM) 40 mg-Amlodipine(AML) 10 mg oral tablets, once a day, for the 8-week, single-blind, run-in Period 1. Then in Period 2, participants would be randomized to this same combination or have hydrochlorothiazide oral tablets (12.5 or 25 mg) added for an additional 8 weeks. All medication is given once a day."}, {"id": "FG001", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5", "description": "Participants could start receiving OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5 oral tablets given once daily in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3."}, {"id": "FG002", "title": "OLM 40-AML 10-HCTZ 25", "description": "Participants could start receiving OLM 40-AML 10-HCTZ 25 oral tablets, given once daily, in randomized, double-blind, 8- week Period 2."}, {"id": "FG003", "title": "OLM 40-AML 10-HCTZ 12.5 (Responders)", "description": "Participants who meet their blood pressure goals (responded) in Period 3 and continued into 8-week, double-blind Period 4 continued to receive OLM 40-AML 10-HCTZ 12.5 oral tablets given once daily."}, {"id": "FG004", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5 (Non-responders)", "description": "Participants finishing Period 3, but, who did not meet their blood pressure goals (non-responders) could receive OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5 oral tablets, given once daily, in double-blind, randomized, Period 4."}, {"id": "FG005", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 25 (Non-responders)", "description": "Participants finishing Period 3, but, who did not meet their blood pressure goals (non-responders) could receive OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 25 oral tablets, given once daily, in double-blind, randomized, Period 4"}], "periods": [{"title": "1-Single-blind, Run-in, Single-Treatment", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "2204"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2086"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "118"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "49"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Other Reason", "reasons": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "2-Randomized Double-blind 3 Treatments", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Only 808 began Period 2 because the others finishing Period 1 did not meet the entry criteria.", "numSubjects": "269"}, {"groupId": "FG001", "numSubjects": "269"}, {"groupId": "FG002", "numSubjects": "270"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "260"}, {"groupId": "FG001", "numSubjects": "263"}, {"groupId": "FG002", "numSubjects": "262"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "6"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "3-Single-blind, Single Treatment", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "comment": "Number starting is \\< total completing previous arm since 3 subjects did not receive at least 1 dose.", "numSubjects": "782"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "767"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "4-Randomized Double-blind 2 Treatments", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "comment": "Period 3 responders were continued on OLM 40-AML 10-HCTZ 12.5", "numSubjects": "467"}, {"groupId": "FG004", "comment": "Period 3 non-responders were randomized to OLM 40-AML 10-HCTZ 12.5 or 25 in a 2:1 ratio", "numSubjects": "97"}, {"groupId": "FG005", "numSubjects": "197"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "458"}, {"groupId": "FG004", "numSubjects": "95"}, {"groupId": "FG005", "numSubjects": "196"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "9"}, {"groupId": "FG004", "numSubjects": "2"}, {"groupId": "FG005", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "1"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "3"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg", "description": "The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2."}, {"id": "BG001", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5", "description": "Participants could start receiving this combination in randomized, double-blind, 8- week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3"}, {"id": "BG002", "title": "OLM 40-AML 10-HCTZ 25", "description": "Participants could start receiving this combination in randomized, double-blind, 8- week Period 2."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "269"}, {"groupId": "BG001", "value": "269"}, {"groupId": "BG002", "value": "270"}, {"groupId": "BG003", "value": "808"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.9", "spread": "10.56"}, {"groupId": "BG001", "value": "56.5", "spread": "10.25"}, {"groupId": "BG002", "value": "54.9", "spread": "10.44"}, {"groupId": "BG003", "value": "55.8", "spread": "10.42"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "119"}, {"groupId": "BG001", "value": "104"}, {"groupId": "BG002", "value": "116"}, {"groupId": "BG003", "value": "339"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "150"}, {"groupId": "BG001", "value": "165"}, {"groupId": "BG002", "value": "154"}, {"groupId": "BG003", "value": "469"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "269"}, {"groupId": "BG001", "value": "269"}, {"groupId": "BG002", "value": "269"}, {"groupId": "BG003", "value": "807"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "87.8", "spread": "18.14"}, {"groupId": "BG001", "value": "88.2", "spread": "16.03"}, {"groupId": "BG002", "value": "88.5", "spread": "16.28"}, {"groupId": "BG003", "value": "88.2", "spread": "16.83"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "169.9", "spread": "9.74"}, {"groupId": "BG001", "value": "170.5", "spread": "9.11"}, {"groupId": "BG002", "value": "170.4", "spread": "8.98"}, {"groupId": "BG003", "value": "170.3", "spread": "9.27"}]}]}]}, {"title": "Body Mass Index", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "30.27", "spread": "4.90"}, {"groupId": "BG001", "value": "30.30", "spread": "4.65"}, {"groupId": "BG002", "value": "30.44", "spread": "4.87"}, {"groupId": "BG003", "value": "30.34", "spread": "4.80"}]}]}]}, {"title": "Obesity", "description": "Number of participants whose Body Mass Index (BMI) is \\<30 kg/m\\^2 or whose number is \\>=30 kg/m\\^2. Only 806 participants had their BMI measured.", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Body Mass Index < 30 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "138"}, {"groupId": "BG001", "value": "142"}, {"groupId": "BG002", "value": "133"}, {"groupId": "BG003", "value": "413"}]}]}, {"title": "Body Mass Index >= 30 kg/m^2", "categories": [{"measurements": [{"groupId": "BG000", "value": "131"}, {"groupId": "BG001", "value": "125"}, {"groupId": "BG002", "value": "137"}, {"groupId": "BG003", "value": "393"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Seated Diastolic Blood Pressure (SeDBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg", "description": "Three cuff blood pressure measurements were taken at each visit.", "populationDescription": "The Full Analysis Set 1 included 806 randomized subjects who received at least 1 dose of double-blind study medication in Period II and provided at least 1 SeDBP measurement in Period II: 269 subjects in the OM/AML 40/10 mg group, 268 subjects in the OM/AML/HCTZ 40/10/12.5 mg group, and 269 subjects in the OM/AML/HCTZ 40/10/25 mg group.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "baseline (8 weeks) to 16 weeks", "groups": [{"id": "OG000", "title": "Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg", "description": "The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2."}, {"id": "OG001", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5", "description": "Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3."}, {"id": "OG002", "title": "OLM 40-AML 10-HCTZ 25", "description": "Participants could start receiving this combination in randomized, double-blind, 8- week Period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "268"}, {"groupId": "OG002", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.1", "spread": "0.55"}, {"groupId": "OG001", "value": "-7.1", "spread": "0.55"}, {"groupId": "OG002", "value": "-8.9", "spread": "0.55"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1187", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in Seated Systolic Blood Pressure (SeSBP) of the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg vs. OM/AML 40/10 mg", "description": "Three cuff blood pressure measurements were taken at each visit.", "populationDescription": "The Full Analysis Set 1 included 806 randomized subjects who received at least 1 dose of double-blind study medication in Period II and provided at least 1 SeDBP measurement in Period II: 269 subjects in the OM/AML 40/10 mg group, 268 subjects in the OM/AML/HCTZ 40/10/12.5 mg group, and 269 subjects in the OM/AML/HCTZ 40/10/25 mg group.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "baseline (8 weeks) to week 16", "groups": [{"id": "OG000", "title": "Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg", "description": "The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2."}, {"id": "OG001", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5", "description": "Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3."}, {"id": "OG002", "title": "OLM 40-AML 10-HCTZ 25", "description": "Participants could start receiving this combination in randomized, double-blind, 8- week Period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "268"}, {"groupId": "OG002", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.9", "spread": "0.76"}, {"groupId": "OG001", "value": "-8.6", "spread": "0.77"}, {"groupId": "OG002", "value": "-10.5", "spread": "0.77"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0425", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Number of Subjects Achieving Blood Pressure (BP) Goal at Week 16.", "description": "Achieving blood pressure goal is defined as seated blood pressure \\<140/90 mm Hg; 130/80 mm Hg for participants with diabetes and/or other chronic renal and/or chronic cardiovascular disease. Three cuff blood pressure measurements were taken at each visit.", "populationDescription": "The Full Analysis Set 1 included 806 randomized subjects who received at least 1 dose of double-blind study medication in Period II and provided at least 1 SeDBP measurement in Period II: 269 subjects in the OM/AML 40/10 mg group, 268 subjects in the OM/AML/HCTZ 40/10/12.5 mg group, and 269 subjects in the OM/AML/HCTZ 40/10/25 mg group.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "baseline (week 8) to week 16", "groups": [{"id": "OG000", "title": "Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg", "description": "The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2."}, {"id": "OG001", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5", "description": "Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3."}, {"id": "OG002", "title": "OLM 40-AML 10-HCTZ 25", "description": "Participants could start receiving this combination in randomized, double-blind, 8- week Period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "268"}, {"groupId": "OG002", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "65"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "111"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1939", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "Cochran-Mantel-Haenszel", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in 24-hour Diastolic Blood Pressure (DBP) Assessed by 24-hour Ambulatory Blood Pressure Measurement (ABPM).", "description": "Three cuff blood pressure measurements were taken at each visit.", "populationDescription": "The Full Analysis Set 1 included 806 randomized subjects who received at least 1 dose of double-blind study medication in Period II and provided at least 1 SeDBP measurement in Period II: 269 subjects in the OM/AML 40/10 mg group, 268 subjects in the OM/AML/HCTZ 40/10/12.5 mg group, and 269 subjects in the OM/AML/HCTZ 40/10/25 mg group.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline (8 weeks) to 16 weeks", "groups": [{"id": "OG000", "title": "Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg", "description": "The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2."}, {"id": "OG001", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5", "description": "Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3."}, {"id": "OG002", "title": "OLM 40-AML 10-HCTZ 25", "description": "Participants could start receiving this combination in randomized, double-blind, 8- week Period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "268"}, {"groupId": "OG002", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.1", "spread": "0.52"}, {"groupId": "OG001", "value": "-4.0", "spread": "0.52"}, {"groupId": "OG002", "value": "-5.3", "spread": "0.52"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0009", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "Change in 24-hour Systolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.", "description": "Three cuff blood pressure measurements were taken at each visit.", "populationDescription": "The Full Analysis Set 1 included 806 randomized subjects who received at least 1 dose of double-blind study medication in Period II and provided at least 1 SeDBP measurement in Period II: 269 subjects in the OM/AML 40/10 mg group, 268 subjects in the OM/AML/HCTZ 40/10/12.5 mg group, and 269 subjects in the OM/AML/HCTZ 40/10/25 mg group.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline (8 weeks) to 16 weeks", "groups": [{"id": "OG000", "title": "Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg", "description": "The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2."}, {"id": "OG001", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5", "description": "Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3."}, {"id": "OG002", "title": "OLM 40-AML 10-HCTZ 25", "description": "Participants could start receiving this combination in randomized, double-blind, 8- week Period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "269"}, {"groupId": "OG001", "value": "268"}, {"groupId": "OG002", "value": "269"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.9", "spread": "0.75"}, {"groupId": "OG001", "value": "-5.1", "spread": "0.75"}, {"groupId": "OG002", "value": "-6.6", "spread": "0.75"}]}]}], "analyses": [{"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "In Non-responders, the Change in Seated Diastolic Blood Pressure Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.", "description": "Change in seated diastolic blood pressure from the beginning to the end of Period 4. Three cuff blood pressure measurements were taken at each visit.", "populationDescription": "The analysis population includes those participants who had blood pressure values at both the beginning and end of Period 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "week 24 to week 32", "groups": [{"id": "OG000", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5 (Non-responders)", "description": "Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4"}, {"id": "OG001", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 25 (Non-responders)", "description": "Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "196"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-6.7", "spread": "0.84"}, {"groupId": "OG001", "value": "-7.9", "spread": "0.69"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1611", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "In Non-responders, the Change in Seated Systolic Blood Pressure Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.", "description": "Change in seated systolic blood pressure from the beginning to the end of Period 4. Three cuff blood pressure measurements were taken at each visit.", "populationDescription": "The analysis population includes those participants who had blood pressure values at both the beginning and end of Period 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "week 24 to week 32", "groups": [{"id": "OG000", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5 (Non-responders)", "description": "Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4"}, {"id": "OG001", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 25 (Non-responders)", "description": "Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "196"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.5", "spread": "1.10"}, {"groupId": "OG001", "value": "-7.8", "spread": "0.89"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0451", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "In Non-responders, the Number of Subject Meeting Their Blood Pressure Goals Associated With the Triple Combinations OM/AML/HCTZ 40/10/12.5 and 40/10/25 mg.", "description": "The number of non-responding participants who achieved their blood pressure goals at the end of Period 4. Achieving blood pressure goal is defined as seated blood pressure \\<140/90 mm Hg; 130/80 mm Hg for participants with diabetes and/or other chronic renal and/or chronic cardiovascular disease. Three cuff blood pressure measurements were taken at each visit.", "populationDescription": "The analysis population includes those participants who had blood pressure values at both the beginning and end of Period 4.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Participants", "timeFrame": "week 24 to week 32", "groups": [{"id": "OG000", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5 (Non-responders)", "description": "Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4"}, {"id": "OG001", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 25 (Non-responders)", "description": "Participants finishing Period 3, but, who did not meet their blood pressure goals could receive this combination in the double-blind, randomized, Period 4"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "196"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "89"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0412", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "In Non-responders, the Change in 24-hour Diastolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.", "description": "In non-responders, the change in 24-hour diastolic blood pressure assessed by 24-hour ambulatory blood pressure measurement from the beginning to the end of Period 4.", "populationDescription": "The analysis population includes those participants who had blood pressure values at both the beginning and end of Period 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Week 16 to week 32", "groups": [{"id": "OG000", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5", "description": "Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3."}, {"id": "OG001", "title": "OLM 40-AML 10-HCTZ 25", "description": "Participants could start receiving this combination in randomized, double-blind, 8- week Period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "196"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.2", "spread": "0.96"}, {"groupId": "OG001", "value": "-4.4", "spread": "0.81"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0253", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}, {"type": "SECONDARY", "title": "In Non-responders, the Change in 24-hour Systolic Blood Pressure Assessed by 24-hour Ambulatory Blood Pressure Measurement.", "description": "In non-responders, the change in 24-hour systolic blood pressure assessed by 24-hour ambulatory blood pressure measurement from the beginning to the end of Period 4.", "populationDescription": "The analysis population includes those participants who had blood pressure values at both the beginning and end of Period 4.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Week 16 to week 32", "groups": [{"id": "OG000", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5", "description": "Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3."}, {"id": "OG001", "title": "OLM 40-AML 10-HCTZ 25", "description": "Participants could start receiving this combination in randomized, double-blind, 8- week Period 2."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "96"}, {"groupId": "OG001", "value": "196"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "1.44"}, {"groupId": "OG001", "value": "-4.3", "spread": "1.21"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0063", "statisticalMethod": "ANCOVA", "ciPctValue": "95"}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Adverse events were collected from screening to 14 days after the last dose of study medication. Adverse events are reported for week 1 through week 16.", "eventGroups": [{"id": "EG000", "title": "Olmesartan(OLM) 40 Mg-Amlodipine(AML) 10 mg", "description": "The participants in this arm received these 2 drugs for the 8-week, single-blind, run-in Period 1. Participants could then randomized to this same combination for an additional 8 weeks in the double-blind, Period 2.", "seriousNumAffected": 18, "seriousNumAtRisk": 2204, "otherNumAffected": 113, "otherNumAtRisk": 2204}, {"id": "EG001", "title": "OLM 40-AML 10-Hydrochlorothiazide (HCTZ) 12.5", "description": "Participants could start receiving this combination in randomized, double-blind, 8-week Period 2. This combination was continued into single-blind, 8-week Period 3 for all participants entering Period 3.", "seriousNumAffected": 15, "seriousNumAtRisk": 269, "otherNumAffected": 7, "otherNumAtRisk": 269}, {"id": "EG002", "title": "OLM 40-AML 10-HCTZ 25", "description": "Participants could start receiving this combination in randomized, double-blind, 8- week Period 2.", "seriousNumAffected": 3, "seriousNumAtRisk": 270, "otherNumAffected": 7, "otherNumAtRisk": 270}], "seriousEvents": [{"term": "Ankle fracture", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Atrial flbrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}]}, {"term": "Atrial flutter", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Cardio-respiratory arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}]}, {"term": "Cerebral infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Erosive oesophagitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Foot fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Hypertensive crisis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Intracardiac thrombus", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Lobar pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Mental disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Musculoskeletal chest pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Osteochondrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Pancreatitis chronic", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Peripheral aterial occlusive disease", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Polycythaemia vera", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 270}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Pseudarthrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Pseudoathrosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Renal failure", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Sciatica", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Spinal claudication", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Status asthmaticus", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Thrombophelibitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Tonsil cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Transient ischemic attack", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}, {"term": "Wrist fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 270}]}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (11.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 113, "numAffected": 113, "numAtRisk": 2204}, {"groupId": "EG001", "numEvents": 7, "numAffected": 7, "numAtRisk": 269}, {"groupId": "EG002", "numEvents": 7, "numAffected": 7, "numAtRisk": 270}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "A site may not publish results until after a multi-center publication has been submitted for publication or until one year after the study has ended, whichever occurs first. Then, the site will have the opportunity to publish the results, provided that Daiichi Sankyo Europe has had the opportunity to review and comment on the site's proposed publication prior to its being submitted for publication with the advice of company patent council and in accord with needs for subject protection."}, "pointOfContact": {"title": "Bettina Ammentorp", "organization": "Daiichi Sankyo Europe GmbH", "email": "bettina.ammentorp@daiichi-sankyo.eu", "phone": "0049 89 7808 0", "phoneExt": "585"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Czech Republic"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}, {"id": "D000075222", "term": "Essential Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M1470", "name": "Essential Hypertension", "asFound": "Essential Hypertension", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000017311", "term": "Amlodipine"}, {"id": "D000006852", "term": "Hydrochlorothiazide"}, {"id": "C000437965", "term": "Olmesartan"}, {"id": "D000068557", "term": "Olmesartan Medoxomil"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000002121", "term": "Calcium Channel Blockers"}, {"id": "D000049990", "term": "Membrane Transport Modulators"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000077264", "term": "Calcium-Regulating Hormones and Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000004232", "term": "Diuretics"}, {"id": "D000045283", "term": "Natriuretic Agents"}, {"id": "D000049993", "term": "Sodium Chloride Symporter Inhibitors"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}], "browseLeaves": [{"id": "M19600", "name": "Amlodipine", "asFound": "Healthy Volunteers", "relevance": "HIGH"}, {"id": "M9910", "name": "Hydrochlorothiazide", "asFound": "Prescription", "relevance": "HIGH"}, {"id": "M91890", "name": "Olmesartan", "asFound": "Anticoagulation", "relevance": "HIGH"}, {"id": "M273", "name": "Olmesartan Medoxomil", "asFound": "Anticoagulation", "relevance": "HIGH"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M5381", "name": "Calcium", "relevance": "LOW"}, {"id": "M5398", "name": "Calcium, Dietary", "relevance": "LOW"}, {"id": "M5384", "name": "Calcium Channel Blockers", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M7411", "name": "Diuretics", "relevance": "LOW"}, {"id": "M26152", "name": "Sodium Chloride Symporter Inhibitors", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "ChanBlk", "name": "Channel Blockers"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "NaAg", "name": "Natriuretic Agents"}, {"abbrev": "BDCA", "name": "Bone Density Conservation Agents"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}]}}, "hasResults": true}